ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Post-Menopausal Osteoporosis

Conditions

Post-Menopausal Osteoporosis

Trial Timeline

Oct 1, 2004 → Nov 1, 2008

NCT ID

NCT00551174

About ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]

ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] is a approved stage product being developed by Roche for Post-Menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00551174. Target conditions include Post-Menopausal Osteoporosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00545480	Approved	Completed	Jul 1, 2006	Mar 1, 2009	Post Menopausal Osteoporosis
NCT00545909	Approved	Completed	Mar 1, 2006	Aug 1, 2008	Postmenopausal Osteoporosis
NCT00551174	Approved	Completed	Oct 1, 2004	Nov 1, 2008	Post-Menopausal Osteoporosis
NCT00081653	Approved	Completed	May 1, 2004	May 1, 2008	Post-Menopausal Osteoporosis

Competing Products

19 competing products in Post-Menopausal Osteoporosis

See all competitors

Product	Company	Stage	Hype Score
raloxifene + Placebo	Eli Lilly	Approved	85
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneous	Eli Lilly	Phase 3	77
Teriparatide + Zoledronic Acid	Eli Lilly	Approved	85
teriparatide	Eli Lilly	Phase 3	77
Raloxifene + Raloxifene + Placebo	Eli Lilly	Approved	85
Teriparatide	Eli Lilly	Approved	85
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneous	Eli Lilly	Phase 3	77
MK0429	Merck	Phase 2	52
PTH134 + Placebo + Forsteo	Novartis	Phase 1	33
Placebo + Zoledronic acid	Novartis	Phase 3	77
zoledronic acid + Any oral bisphosphonates marketed in Canada	Novartis	Pre-clinical	23
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + Alendronate	Roche	Approved	85
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]	Roche	Approved	85
Placebo + ibandronate [Bonviva/Boniva]	Roche	Approved	85
ibandronate [Bonviva/Boniva] + Placebo	Roche	Phase 3	77
Ibandronate	Roche	Phase 3	77
romosozumab HCP administration with PFS	Amgen	Phase 3	76
Romosozumab + Alendronate (Fosamax) + Placebo Romosozumab + Placebo Alendronate	Amgen	Phase 2	51
BAY3427080 + Placebo (for BAY3427080)	Bayer	Phase 1/2	38

Other Products from Roche

EmicizumabApproved

rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved

RituximabApproved

mycophenolate mofetil [CellCept]Approved

saquinavir/ritonavir + atazanavir/ritonavirApproved